TCRT | Alaunos Therapeutics
Next ER: August 15, 2022 Before Market Opens
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, covering common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR. Alaunos is developing non-viral gene transfer-based cell therapies to effectively access and treat the millions of people diagnosed globally each year with solid tumors by weaponizing the body's immune system.
NASDAQ - Nasdaq Stock Market
More profiles and info about the company
This company doesn't provide a dividend.
Talk about Alaunos Therapeutics below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
If you are looking for News & events, Press Release, they are available on their Investors Relationssite.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
Buy on Amazon
Currency Trading For Dummies is a hands-on, user-friendly guide that explains how the foreign exchange (ForEx) market works and how you can become a part of it. Currency trading has many benefits, but it also has fast-changing financial-trading avenues. ForEx markets are always moving. So how do you keep up?